Prognosis of stage IIB cervical cancer among treatment regimens: Radical hysterectomy vs. neoadjuvant chemotherapy followed by radical hysterectomy vs. concurrent chemoradiotherapy

Woo, Young Ju; Byun, Jung Mi; Jeong, Dae Hoon; Kim, Young Nam; Kim, Su Seon; Seo, Young Jin; Sung, Moon Su; Lee, Kyoung Bok; Kim, Ki Tae

doi:10.5468/kjog.2012.55.12.913

Cited by 3 publications

(1 citation statement)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Radiotherapy alone offers a 5-year survival rate of about 60% in stage IIB, 30-35% in Stage IIIB, and less than 15% in stage IVA disease. Almost 40-60% of these patients will develop local recurrence while distant failure in about 20-25% patients [17].…”

Section: Introductionmentioning

confidence: 99%

Neoadjuvant chemotherapy with paclitaxel and carboplatin followed by definitive chemoradiation in locally advanced cervical carcinoma. Experience of a cancer hospital in Pakistan

Sadaf¹,

Javed²,

Rashid³

et al. 2021

European Journal of Gynaecological Oncology

View full text Add to dashboard Cite

To report the efficacy and toxicity of neoadjuvant chemotherapy (NACT) before standard concurrent chemo radiation (CCRT) in locally advanced carcinoma of cervix. Methods: Between January 2007 and December 2016, 75 patients with locally advanced cervical cancer treated with neoadjuvant chemotherapy comprising carboplatin area under curve (AUC) 5 and Paclitaxel 175 mg/m 2 followed by chemo radiotherapy 45-59 Gy in 25-28 fractions with concurrent cisplatin and high dose rate (HDR) brachytherapy at our institution were analyzed. Clinical response rate, disease free survival, overall survival and toxicity was evaluated and documented using European organization for research and treatment of cancer (EORTC) criteria. Results: Baseline characteristics were median age at diagnosis 48 years; 86% squamous, and 14% adenocarcinoma histology; The international Federation of Gynecology and Obstetrics (FIGO) stage IB2-IIB (47%), III-IVA (53%). 64% had nodes involved and 84% had primary more than 4 cm in diameter. Complete or partial response rate was (95%) post-NACT and 92% (95% CI: 71-94) post-CRT. The median follow-up was 39.1 months. Overall and progression-free survivals at 4 years were 77% and 80% respectively. Grade ¾ hematological toxicities were 7% during NACT (11% hematological, 9% non-hematological) and 8% during CRT. The most common non hematological toxicity was diarrhea in 10%. The delayed toxicities at 24 months or later after CRT completion were rectal (11%), bladder (3%), and vaginal (28%). Conclusion: Neoadjuvant chemotherapy in locally advanced cervical cancer offers a favorable paradigm as reflected by acceptable toxicity and is associated with a high response rate in locally advanced cervical cancer. However, further randomized clinical trials are needed to support this evidence.

show abstract

Section: Introductionmentioning

confidence: 99%

Neoadjuvant chemotherapy with paclitaxel and carboplatin followed by definitive chemoradiation in locally advanced cervical carcinoma. Experience of a cancer hospital in Pakistan

Sadaf¹,

Javed²,

Rashid³

et al. 2021

European Journal of Gynaecological Oncology

View full text Add to dashboard Cite

show abstract

Pros and Cons of Adding of Neoadjuvant Chemotherapy to Standard Concurrent Chemoradiotherapy in Cervical Cancer: A Regional Cancer Center Experience

Narayan

Sharma

Kapoor

et al. 2015

J Obstet Gynecol India

View full text Add to dashboard Cite

Background The present study summarizes the results of treatment in the form of disease-free survival and overall survival in bulky stage IB2 and locally advanced (stages II-IVA) squamous cell carcinoma of the uterine cervix. The treatment has been given in the form of NACT followed by CCRT in one arm and CCRT in the other arm. The grade 3/4 hematologic toxicities were more in the NACT group than CCRT (p \ 0.001) while the non-hematological toxicity was not significant; the TPF group experienced more toxicity than PF (p = 0.029). This treatment regimen is feasible as evidenced by the acceptable toxicity of NACT and by the high compliance to radiotherapy. The grade 3/4 hematologic toxicities were more in NACT groups than CCRT (p \ 0.001); the TPF group experienced more toxicity than PF (p = 0.029). Materials and Methods

show abstract

Pros and Cons of Adding of Neoadjuvant Chemotherapy to Standard Concurrent Chemoradiotherapy in Cervical Cancer: a Regional Cancer Center Experience

Narayan¹,

Kapoor²,

Bagri³

et al. 2014

Annals of Oncology

View full text Add to dashboard Cite

Prognosis of stage IIB cervical cancer among treatment regimens: Radical hysterectomy vs. neoadjuvant chemotherapy followed by radical hysterectomy vs. concurrent chemoradiotherapy

Cited by 3 publications

References 22 publications

Neoadjuvant chemotherapy with paclitaxel and carboplatin followed by definitive chemoradiation in locally advanced cervical carcinoma. Experience of a cancer hospital in Pakistan

Neoadjuvant chemotherapy with paclitaxel and carboplatin followed by definitive chemoradiation in locally advanced cervical carcinoma. Experience of a cancer hospital in Pakistan

Pros and Cons of Adding of Neoadjuvant Chemotherapy to Standard Concurrent Chemoradiotherapy in Cervical Cancer: A Regional Cancer Center Experience

Pros and Cons of Adding of Neoadjuvant Chemotherapy to Standard Concurrent Chemoradiotherapy in Cervical Cancer: a Regional Cancer Center Experience

Contact Info

Product

Resources

About